The "Atopic Dermatitis (AD) - Market Insights, Epidemiology and Market Forecasts to 2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
According to research, the global market of Atopic Dermatitis was estimated to be USD 2.2 billion in 2016.
The prevalent population of Atopic Dermatitis was estimated to be 40.78 Million [7MM] in 2016. United States accounts for the highest AD Cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Adults are largely affected with the Atopic Dermatitis. Among EU5, France has been reported to have the highest prevalent population of Atopic Dermatitis.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Atopic Dermatitis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Atopic Dermatitis from 2016 to 2027 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assess underlying potential of the market.
Companies Mentioned:
- Dermata Therapeutics
- DS Biopharma
- Galderma Pharma
- GlaxoSmithKline
- LEO Pharma
- Menlo Therapeutics
- Nippon Shinyaku
- Novartis
- Otsuka Pharmaceutical
- Roche
- Roivant Sciences
- Tioga Pharmaceuticals
- Vanda Pharmaceuticals
Key Topics Covered:
1. Report Introduction
2. Atopic Dermatitis Market Overview at a Glance
3. Disease Background and Overview
4. Epidemiology and Patient Population
5. Treatment Practices
6. Treatment Algorithm
7. Treatment Failure
8. Emerging Therapies
9. Nemolizumab: Galderma Pharma
10. Tralokinumab: LEO Pharma
11. Tradipitant: Vanda Pharmaceuticals
12. ZPL-389: Novartis
13. NST-141: Nippon Shinyaku
14. Serlopitant: Menlo Therapeutics
15. DS107: DS Biopharma
16. Asimadoline: Tioga Pharmaceuticals
17. GSK2894512: GlaxoSmithKline
18. Lebrikizumab: Roche
19. DMT210: Dermata Therapeutics
20. RVT-501: Roivant Sciences
21. OPA-15406: Otsuka Pharmaceutical
22. Current Unmet Need
23. Atopic Dermatitis: Market Analysis
24. Atopic Dermatitis: United States Market Outlook
25. Atopic Dermatitis: EU5 Market Outlook
26. Atopic Dermatitis: Japan Market Outlook
27. Market Drivers
28. Market Barriers
29. Expert Opinions
30. Views on Current Treatment Options
31. Views on Emerging Therapies
32. Appendix
33. Report Methodology
34. Capabilities
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/v5rnv9/global_atopic?w=4
View source version on businesswire.com: http://www.businesswire.com/news/home/20180222005953/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Dermatology,
Dermatological
Drugs